DNMT3A facilitates breast cancer progression via regulating ADAMTS8 mediated EGFR-MEK-ERK activation
PLOS One · 2025
DOI: 10.1371/journal.pone.0321889 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Shan Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. Hauptthemen laut MEDLINE: Breast Neoplasms, DNA (Cytosine-5-)-Methyltransferases, MAP Kinase Signaling System, ADAMTS Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The government of Hebei Province supports the outstanding talents project.
Abstract (Originalsprache)
ADAMTS8 inactivation by epigenetic modifications has been reported in various tumors, and the dysregulation of ADAMTS8 expression is associated with poor clinical outcomes, cancer cell invasion, and metastasis. De novo methylation, involving DNMT3A, plays an important role in cancer development; however, it remains unclear whether DNMT3A regulates the progressive expression of breast cancer by regulating ADAMTS8. Through published cancer-related datasets and clinical validation, we found that ADAMTS8 and DNMT3A expression negatively correlated in breast cancer, and both associated with patient prognosis. Related cell experiments have shown that DNMT3A overexpression promotes breast cancer cell proliferation, migration, invasion, and apoptosis, whereas silencing DNMT3A has the opposite effect. Through Co-IP experiments, we confirmed that DNMT3A binds directly to ADAMTS8. Methylation-specific PCR (MSP) experiments confirmed that DNMT3A mediates ADAMTS8 promoter methylation in breast cancer. In addition, DNMT3A activated the EGFR-MEK-ERK signaling pathway by effectively downregulating ADAMTS8, whereas silencing ADAMTS8 effectively inhibited this signaling pathway. Taken together, our findings suggest that DNMT3A activates the EGFR-MEK-ERK signaling pathway by silencing ADAMTS8 transcription through methylation, thereby promoting breast cancer development. Therefore, DNMT3A may serve as an inhibitory target in breast cancer-targeted therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
- Hebei Key Laboratory of Breast Cancer Molecular Medicine, Shijiazhuang, Hebei, China.
ORCID-Profile: Sainan Li
Förderung
- The government of Hebei Province supports the outstanding talents project
Zitieren
APA
Yang, S., Cheng, M., Zhang, S., Wang, H., Wang, J., Zhang, X., Mi, Y., & Li, S. (2025). DNMT3A facilitates breast cancer progression via regulating ADAMTS8 mediated EGFR-MEK-ERK activation. PLOS One. https://doi.org/10.1371/journal.pone.0321889
Vancouver
Yang S, Cheng M, Zhang S, Wang H, Wang J, Zhang X, et al. DNMT3A facilitates breast cancer progression via regulating ADAMTS8 mediated EGFR-MEK-ERK activation. PLOS One. 2025. doi:10.1371/journal.pone.0321889
BibTeX
@article{Yang2025,
author = {Yang, Shan and Cheng, Meng and Zhang, Shaonan and Wang, Haoqi and Wang, Jiaxing and Zhang, Xi and Mi, Yunzhe and Li, Sainan},
title = {DNMT3A facilitates breast cancer progression via regulating ADAMTS8 mediated EGFR-MEK-ERK activation},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0321889}
}
EUVIMED